NanoString Technologies Releases Operating Results for Second Quarter of 2022
NanoString Technologies reported a strong second quarter for 2022, with product and service revenue of $32.0 million, a significant 65% year-over-year increase in orders for spatial biology instruments, including over 25 CosMx systems. Despite this growth, the company anticipates a total revenue of $140 to $150 million, lower than previous guidance, due to an expected mix shift in orders. The company also reported a net loss of $39.2 million for the quarter and updated its adjusted EBITDA loss guidance to $75 to $85 million.
- Orders for spatial biology instruments increased by 65% year-over-year.
- Secured 25+ orders for CosMx Spatial Molecular Imagers, contributing to a growing revenue backlog.
- Total product and service revenue of $32.0 million in Q2 2022.
- Total revenue guidance revised down to $140-$150 million from $150-$160 million.
- Net loss of $39.2 million reported for the quarter.
- Adjusted EBITDA loss projected to worsen to $75-$85 million.
Generated Orders for ~ 50 Spatial Biology Instruments, Representing
Second Quarter Financial Highlights
-
Product and service revenue of
$32.0 million -
GeoMx® Digital Spatial Profiler (DSP) revenue of
. GeoMx DSP revenue includes:$10.9 million -
Instrument revenue of
$5.2 million -
Consumables revenue of
, annualized pull-through of approximately$5.7 million per installed system$77,000
-
Instrument revenue of
-
nCounter® revenue, inclusive of all service revenue, of
. nCounter revenue includes:$21.1 million -
Instrument revenue of
$4.3 million -
Consumables revenue of
, annualized pull-through of approximately$12.2 million per installed system$45,000 -
Service revenue of
$4.6 million
-
Instrument revenue of
-
Cash, cash equivalents and short-term investments balance of
$272.3 million
“NanoString had an excellent second quarter, as our commercial execution continued to improve, and laboratories adopting our solutions drove a
Operational Highlights
Spatial Biology
- CosMx Orders: Secured customer orders for more than 25 CosMx™ Spatial Molecular Imager (SMI) systems, bringing total orders to date to more than 60 systems
- Commercial Status: First CosMx beta instrument was shipped to a customer during the first week of August, with two additional beta instruments scheduled for shipments to customers later in August
-
Advances in
Genome Biology and Technology (AGBT) Conference : Unveiled the AtoMx Spatial Informatics Platform and showcased data from 20 spatial biology studies, including 15 for CosMx SMI - Introduced Integrated Informatics Platform for GeoMx Using NGS: Began offering a streamlined end-to-end solution to fully integrate GeoMx with Illumina NextSeq sequencers
-
GeoMx Installed Base: Grew installed base to approximately 315 GeoMx DSP Systems at
June 30, 2022 , representing66% growth over the prior year -
Publications: Continued growth of peer-reviewed publications utilizing GeoMx DSP technology, with approximately 20 new publications in the second quarter, bringing the cumulative total to approximately 130 peer-reviewed publications as of
June 30, 2022
nCounter
-
nCounter Installed Base: Grew installed base to approximately 1,085 nCounter Analysis Systems at
June 30, 2022 , representing7% growth over the prior year -
Publications: Surpassed 5,800 cumulative peer-reviewed publications utilizing nCounter technology at
June 30, 2022
2022 Outlook
The company updated its 2022 outlook, with results expected as follows:
-
Orders for about 200 spatial biology systems, consistent with previous guidance, with an expected mix now comprised of approximately
50% GeoMx system orders and approximately50% CosMx system orders -
Cumulative orders for approximately 120 CosMx systems expected by the end of 2022, providing a revenue backlog valued at approximately
$30 million -
Total product and service revenue of
to$140 , as compared to previous guidance of$150 million to$150 , reflecting an order mix that is weighted more heavily to CosMx, with material CosMx revenue recognition expected to begin in 2023$160 million -
nCounter revenue, inclusive of all service revenue, of
to$90 , consistent with previous guidance$95 million -
Adjusted EBITDA loss of
to$75 , as compared to previous guidance of$85 million to$65 $75 million
Financial Results
We have elected to present selected non-GAAP, or adjusted, financial measures, including Adjusted EBITDA. These adjusted financial measures are calculated excluding certain items that may make it more challenging to compare our GAAP operating results across periods. Such items may include collaboration revenue, stock-based compensation, depreciation and amortization, or one-time charges such as transaction related fees and expenses or restructuring charges and severance costs. A reconciliation of adjusted financial measures to the nearest comparable GAAP financial measure can be found in the tables at the end of this press release.
(dollars in thousands) |
Three Months Ended |
||||||||||||||
|
GAAP |
|
Non-GAAP Adjusted |
||||||||||||
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Product and service revenue |
$ |
31,998 |
|
|
$ |
33,632 |
|
|
$ |
31,998 |
|
|
$ |
33,632 |
|
Collaboration revenue |
|
221 |
|
|
|
231 |
|
|
|
— |
|
|
|
— |
|
Total revenue |
|
32,219 |
|
|
|
33,863 |
|
|
|
31,998 |
|
|
|
33,632 |
|
Cost of product and service revenue |
|
15,852 |
|
|
|
15,481 |
|
|
|
14,756 |
|
|
|
14,735 |
|
Gross Margin |
|
50 |
% |
|
|
54 |
% |
|
|
54 |
% |
|
|
56 |
% |
Research and development |
|
17,346 |
|
|
|
17,162 |
|
|
|
14,474 |
|
|
|
14,469 |
|
Selling, general and administrative |
|
36,112 |
|
|
|
26,855 |
|
|
|
30,224 |
|
|
|
21,717 |
|
Adjusted EBITDA |
|
N / A |
|
|
|
N / A |
|
|
$ |
(27,456 |
) |
|
$ |
(17,289 |
) |
|
|
|
|
|
|
|
|
||||||||
Non-operating expense, net |
|
(2,148 |
) |
|
|
(1,385 |
) |
|
|
(2,148 |
) |
|
|
(1,385 |
) |
Net loss |
$ |
(39,239 |
) |
|
$ |
(27,020 |
) |
|
$ |
(29,604 |
) |
|
$ |
(18,674 |
) |
|
|
|
|
|
|
|
|
||||||||
|
Six Months Ended |
||||||||||||||
|
GAAP |
|
Non-GAAP Adjusted |
||||||||||||
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Product and service revenue |
$ |
62,839 |
|
|
$ |
65,026 |
|
|
$ |
62,839 |
|
|
$ |
65,026 |
|
Collaboration revenue |
|
460 |
|
|
|
454 |
|
|
|
— |
|
|
|
— |
|
Total revenue |
|
63,299 |
|
|
|
65,480 |
|
|
|
62,839 |
|
|
|
65,026 |
|
Cost of product and service revenue |
|
30,630 |
|
|
|
31,104 |
|
|
|
28,545 |
|
|
|
29,762 |
|
Gross Margin |
|
51 |
% |
|
|
52 |
% |
|
|
55 |
% |
|
|
54 |
% |
Research and development |
|
34,763 |
|
|
|
32,225 |
|
|
|
29,430 |
|
|
|
27,042 |
|
Selling, general and administrative |
|
72,467 |
|
|
|
53,654 |
|
|
|
59,621 |
|
|
|
42,675 |
|
Adjusted EBITDA |
|
N / A |
|
|
|
N / A |
|
|
$ |
(54,757 |
) |
|
$ |
(34,453 |
) |
|
|
|
|
|
|
|
|
||||||||
Non-operating expense, net |
|
(4,178 |
) |
|
|
(3,229 |
) |
|
|
(4,178 |
) |
|
|
(3,229 |
) |
Net loss |
$ |
(78,739 |
) |
|
$ |
(54,732 |
) |
|
$ |
(58,935 |
) |
|
$ |
(37,682 |
) |
|
|
|
|
|
|
|
|
Supplemental Information
As a supplement to the table above, we have posted to the investor relations section of our website, at www.nanostring.com/Investor Relations/Financials/Quarterly Results, supplemental financial data that include our adjusted financial measures as compared to the nearest comparable GAAP financial measures, for the second quarter and the six months ended
Conference Call
Management will host a conference call today beginning at
Non-GAAP, or Adjusted, Financial Information
We believe that the presentation of non-GAAP, or adjusted, financial information provides important supplemental information to management and investors regarding financial and business trends relating to our financial condition and results of operations. Reconciliation of adjusted financial measures to the most directly comparable financial result as determined in accordance with GAAP are included at the end of this press release following the accompanying financial data. A reconciliation of adjusted guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding certain expenses that may be incurred in the future. For further information regarding why we believe that these adjusted measures provide useful information to investors, the specific manner in which management uses these measures and some of the limitations associated with the use of these measures, please refer to “Notes Regarding Non-GAAP Financial Information” at the end of this press release.
About
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding expectations for demand for our products and growth in our business, future revenue growth, the impact of the COVID-19 pandemic on our operations and future financial performance, the impact of new products and expansion into new markets, the growth trajectory of our nCounter, GeoMx and CosMx franchises, the anticipated launch of new products and technology and our estimated 2022 operating results and our anticipated GAAP and non-GAAP operating results. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; the extent and duration of the impact of the COVID-19 pandemic and adverse conditions in the general domestic and global economic markets; the effects of ongoing litigation; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing and product development; as well as the other risks set forth in our filings with the
The
|
|||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
|||||||||||||||
(In thousands, except per share amounts) |
|||||||||||||||
(Unaudited) |
|||||||||||||||
|
Three Months Ended
|
|
Six Months Ended
|
||||||||||||
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Revenue: |
|
|
|
|
|
|
|
||||||||
Instruments |
$ |
9,538 |
|
|
$ |
11,816 |
|
|
$ |
18,641 |
|
|
$ |
23,561 |
|
Consumables |
|
17,847 |
|
|
|
17,981 |
|
|
|
35,315 |
|
|
|
33,944 |
|
Services |
|
4,613 |
|
|
|
3,835 |
|
|
|
8,883 |
|
|
|
7,521 |
|
Total product and service revenue |
|
31,998 |
|
|
|
33,632 |
|
|
|
62,839 |
|
|
|
65,026 |
|
Collaboration |
|
221 |
|
|
|
231 |
|
|
|
460 |
|
|
|
454 |
|
Total revenue |
|
32,219 |
|
|
|
33,863 |
|
|
|
63,299 |
|
|
|
65,480 |
|
Costs and expenses: |
|
|
|
|
|
|
|
||||||||
Cost of product and service revenue |
|
15,852 |
|
|
|
15,481 |
|
|
|
30,630 |
|
|
|
31,104 |
|
Research and development |
|
17,346 |
|
|
|
17,162 |
|
|
|
34,763 |
|
|
|
32,225 |
|
Selling, general and administrative |
|
36,112 |
|
|
|
26,855 |
|
|
|
72,467 |
|
|
|
53,654 |
|
Total costs and expenses (a) (b) |
|
69,310 |
|
|
|
59,498 |
|
|
|
137,860 |
|
|
|
116,983 |
|
Loss from operations |
|
(37,091 |
) |
|
|
(25,635 |
) |
|
|
(74,561 |
) |
|
|
(51,503 |
) |
Other income (expense): |
|
|
|
|
|
|
|
||||||||
Interest income |
|
406 |
|
|
|
231 |
|
|
|
557 |
|
|
|
349 |
|
Interest expense |
|
(1,880 |
) |
|
|
(1,868 |
) |
|
|
(3,763 |
) |
|
|
(3,738 |
) |
Other income expense, net |
|
(490 |
) |
|
|
334 |
|
|
|
(707 |
) |
|
|
302 |
|
Total other expense, net |
|
(1,964 |
) |
|
|
(1,303 |
) |
|
|
(3,913 |
) |
|
|
(3,087 |
) |
Net loss before provision for income taxes |
|
(39,055 |
) |
|
|
(26,938 |
) |
|
|
(78,474 |
) |
|
|
(54,590 |
) |
Provision for income taxes |
|
(184 |
) |
|
|
(82 |
) |
|
|
(265 |
) |
|
|
(142 |
) |
Net loss |
$ |
(39,239 |
) |
|
$ |
(27,020 |
) |
|
$ |
(78,739 |
) |
|
$ |
(54,732 |
) |
Net loss per share, basic and diluted |
$ |
(0.85 |
) |
|
$ |
(0.60 |
) |
|
$ |
(1.70 |
) |
|
$ |
(1.22 |
) |
Weighted average shares used in computing basic and diluted net loss per share |
|
46,427 |
|
|
|
45,274 |
|
|
|
46,201 |
|
|
|
44,973 |
|
|
|
|
|
|
|
|
|
||||||||
(a) Includes |
|||||||||||||||
(b) Includes |
|||||||||||||||
|
|||||
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||
(In thousands) |
|||||
(Unaudited) |
|||||
|
|
|
|
||
Assets |
|
|
|
||
Current assets: |
|
|
|
||
Cash and cash equivalents |
$ |
126,027 |
|
$ |
107,068 |
Short-term investments |
|
146,315 |
|
|
241,821 |
Accounts receivable, net |
|
31,404 |
|
|
40,130 |
Inventory, net |
|
41,524 |
|
|
31,486 |
Prepaid expenses and other |
|
9,427 |
|
|
7,115 |
Total current assets |
|
354,697 |
|
|
427,620 |
Property and equipment, net |
|
35,414 |
|
|
27,043 |
Operating lease right-of-use assets |
|
17,645 |
|
|
19,226 |
Other assets |
|
5,623 |
|
|
5,592 |
Total assets |
$ |
413,379 |
|
$ |
479,481 |
Liabilities and Stockholders’ Equity |
|
|
|
||
Current liabilities: |
|
|
|
||
Accounts payable |
$ |
16,292 |
|
$ |
14,283 |
Accrued liabilities |
|
6,999 |
|
|
6,765 |
Accrued compensation and other employee benefits |
|
13,729 |
|
|
17,466 |
Customer deposits |
|
1,588 |
|
|
1,278 |
Deferred revenue and other liabilities, current portion |
|
7,987 |
|
|
7,474 |
Operating lease liabilities, current portion |
|
5,249 |
|
|
4,889 |
Total current liabilities |
|
51,844 |
|
|
52,155 |
Deferred revenue and other liabilities, net of current portion |
|
3,857 |
|
|
3,527 |
Long-term debt, net |
|
225,877 |
|
|
225,144 |
Operating lease liabilities, net of current portion |
|
19,136 |
|
|
21,693 |
Total liabilities |
|
300,714 |
|
|
302,519 |
Total stockholders’ equity |
|
112,665 |
|
|
176,962 |
Total liabilities and stockholders’ equity |
$ |
413,379 |
|
$ |
479,481 |
Notes Regarding Non-GAAP Financial Information. In addition to our results reported in accordance with
Expenses excluded from non-GAAP, or adjusted, cost of product and service revenue, research and development expense and selling, general and administrative expense and net loss. We exclude stock-based compensation expense and depreciation and amortization expense, which are non-cash expenses, from certain of our adjusted financial measures because we believe that excluding such items provides meaningful supplemental information regarding operational performance. We exclude certain expenses related to collaborations, recoveries of certain previously remitted state and local taxes, cloud computing arrangement implementation expenses, litigation expenses, and other business development expenses from certain of our adjusted financial measures because such expenses have no direct correlation to the continuing operation of our business as such expenses are non-recurring or non-operating in nature, and therefore we believe excluding these items provides meaningful supplemental information regarding operational performance.
Adjusted EBITDA. Adjusted EBITDA is a non-GAAP financial measure defined as GAAP net loss adjusted for collaboration revenue, stock-based compensation expense, depreciation and amortization, net interest expense, other non-operating expense or income, provision for income tax and other special items as determined by management, including certain expenses related to collaborations, recoveries of certain previously remitted state and local taxes, cloud computing arrangement implementation expenses, litigation expenses, and other business development expenses.
The following tables reflect the reconciliation between GAAP and non-GAAP measures (in thousands).
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
Net loss - GAAP |
$ |
(39,239 |
) |
|
$ |
(27,020 |
) |
|
$ |
(78,739 |
) |
|
$ |
(54,732 |
) |
Collaboration revenue |
|
(221 |
) |
|
|
(231 |
) |
|
|
(460 |
) |
|
|
(454 |
) |
Stock-based compensation |
|
6,458 |
|
|
|
7,989 |
|
|
|
14,125 |
|
|
|
15,405 |
|
Depreciation and amortization |
|
1,961 |
|
|
|
1,439 |
|
|
|
3,504 |
|
|
|
2,880 |
|
Interest expense, net |
|
1,474 |
|
|
|
1,637 |
|
|
|
3,206 |
|
|
|
3,389 |
|
Other (income) expense, net |
|
490 |
|
|
|
(334 |
) |
|
|
707 |
|
|
|
(302 |
) |
Provision for income taxes |
|
184 |
|
|
|
82 |
|
|
|
265 |
|
|
|
142 |
|
Other business development expenses |
|
44 |
|
|
|
45 |
|
|
|
393 |
|
|
|
115 |
|
Litigation expenses |
|
1,237 |
|
|
|
— |
|
|
|
1,930 |
|
|
|
— |
|
Recovery of certain previously remitted state and local taxes |
|
— |
|
|
|
(896 |
) |
|
|
— |
|
|
|
(896 |
) |
Cloud computing arrangement implementation expenses |
|
156 |
|
|
|
— |
|
|
|
312 |
|
|
|
— |
|
Adjusted EBITDA - non-GAAP |
|
(27,456 |
) |
|
|
(17,289 |
) |
|
|
(54,757 |
) |
|
|
(34,453 |
) |
Non-operating expense, net |
|
(2,148 |
) |
|
|
(1,385 |
) |
|
|
(4,178 |
) |
|
|
(3,229 |
) |
Net loss - non-GAAP |
$ |
(29,604 |
) |
|
$ |
(18,674 |
) |
|
$ |
(58,935 |
) |
|
$ |
(37,682 |
) |
|
Three Months Ended |
|
Six Months Ended |
||||||||||||
|
|
2022 |
|
|
|
2021 |
|
|
|
2022 |
|
|
|
2021 |
|
GAAP Total revenue |
$ |
32,219 |
|
|
$ |
33,863 |
|
|
$ |
63,299 |
|
|
$ |
65,480 |
|
Collaboration revenue |
|
(221 |
) |
|
|
(231 |
) |
|
|
(460 |
) |
|
|
(454 |
) |
Non-GAAP Total revenue |
$ |
31,998 |
|
|
$ |
33,632 |
|
|
$ |
62,839 |
|
|
$ |
65,026 |
|
|
|
|
|
|
|
|
|
||||||||
GAAP Cost of product and service revenue |
$ |
15,852 |
|
|
$ |
15,481 |
|
|
$ |
30,630 |
|
|
$ |
31,104 |
|
Stock-based compensation |
|
(699 |
) |
|
|
(585 |
) |
|
|
(1,275 |
) |
|
|
(1,025 |
) |
Depreciation and amortization |
|
(397 |
) |
|
|
(161 |
) |
|
|
(810 |
) |
|
|
(317 |
) |
Non-GAAP Cost of product and service revenue |
$ |
14,756 |
|
|
$ |
14,735 |
|
|
$ |
28,545 |
|
|
$ |
29,762 |
|
|
|
|
|
|
|
|
|
||||||||
GAAP Gross Margin |
|
50 |
% |
|
|
54 |
% |
|
|
51 |
% |
|
|
52 |
% |
Non-GAAP Gross Margin |
|
54 |
% |
|
|
56 |
% |
|
|
55 |
% |
|
|
54 |
% |
|
|
|
|
|
|
|
|
||||||||
|
$ |
17,346 |
|
|
$ |
17,162 |
|
|
$ |
34,763 |
|
|
$ |
32,225 |
|
Stock-based compensation |
|
(1,818 |
) |
|
|
(1,658 |
) |
|
|
(3,561 |
) |
|
|
(3,041 |
) |
Depreciation and amortization |
|
(1,054 |
) |
|
|
(990 |
) |
|
|
(1,772 |
) |
|
|
(2,027 |
) |
Other business development activities |
|
— |
|
|
|
(45 |
) |
|
|
— |
|
|
|
(115 |
) |
|
$ |
14,474 |
|
|
$ |
14,469 |
|
|
$ |
29,430 |
|
|
$ |
27,042 |
|
|
|
|
|
|
|
|
|
||||||||
GAAP Selling, general and administrative |
$ |
36,112 |
|
|
$ |
26,855 |
|
|
$ |
72,467 |
|
|
$ |
53,654 |
|
Stock-based compensation |
|
(3,941 |
) |
|
|
(5,746 |
) |
|
|
(9,289 |
) |
|
|
(11,339 |
) |
Depreciation and amortization |
|
(510 |
) |
|
|
(288 |
) |
|
|
(922 |
) |
|
|
(536 |
) |
Other business development activities |
|
(44 |
) |
|
|
— |
|
|
|
(393 |
) |
|
|
— |
|
Litigation expenses |
|
(1,237 |
) |
|
|
— |
|
|
|
(1,930 |
) |
|
|
— |
|
Recovery of certain previously remitted state and local taxes |
|
— |
|
|
|
896 |
|
|
|
— |
|
|
|
896 |
|
Cloud computing arrangements implementation expense |
|
(156 |
) |
|
|
— |
|
|
|
(312 |
) |
|
|
— |
|
Non-GAAP Selling, general and administrative |
$ |
30,224 |
|
|
$ |
21,717 |
|
|
$ |
59,621 |
|
|
$ |
42,675 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005806/en/
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768
Source:
FAQ
What is NanoString Technologies' stock symbol?
What was the revenue for NanoString in the second quarter of 2022?
How much did orders for spatial biology systems grow year-over-year?
What is the expected revenue backlog from CosMx system orders?